Effective immediately, OPTN Policy 1.4.F has been reinstated, addressing data submission requirements for transplant candidates in cases where data collection is affected by the COVID-19 outbreak.
OPTN Policy 1.4.F has been reinstated, which authorizes transplant programs, as needed, to “carry forward” the most recent clinical data available when obtaining updated data is not feasible due to effects of the COVID-19 pandemic.
Update: FDA to expand use of Pfizer-BioNTech vaccine. Winter 2022 regional meetings and site surveys will be virtual.
FDA approves antibody-based COVID-19 prophylaxis for immunocompromised people
Site surveys to gradually transition to in-person visits starting in December
Watch webinar: What does COVID-19 Vaccine mean for transplanted children?